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CASE REPORTGlioblastoma multiforme as initial internal
malignancy in Muir-Torre syndrome (MTS)
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uir-Torre syndrome (MTS) is an
autosomal-dominant variant of Lynch he-
reditary cancer syndrome. MTS is defined
by sebaceous neoplasms occurring in association
with 1 or more internal malignancies.1 The seba-
ceous neoplasms that characterize MTS are rare
among the general population and include seba-
ceous adenoma, sebaceoma, sebaceous carcinoma,
keratoacanthoma with sebaceous differentiation,
and basal cell carcinoma with sebaceous differenti-
ation.2 A recent case series described several central
nervous system (CNS) malignancies associated with
MTS occurring after the development of colon can-
cer.3 We report a case of MTS with glioblastoma
multiforme as the initial internal malignancy.
CASE REPORT
A 69-year-old Caucasian man presented for eval-
uation of 2 separate orange-yellow papules with
telangiectases of the side of the neck and upper
aspect of the back (Fig 1). Shave biopsy specimen of
the lesions demonstrated sebaceous carcinoma and
sebaceous adenoma, respectively. He had a personal
history of 3 prior sebaceous carcinomas diagnosed at
age 58, 65, and 68 years and 1 sebaceous adenoma
diagnosed at age 66 years. In addition he had a family
history of colon, breast, and renal carcinoma in his
grandfather, mother, and brother, respectively.
The patient had no personal history of internal
malignancy. Because of family history and multiple
sebaceous neoplasms, immunohistochemistry (IHC)
for MSH-2, MSH-6, MLH-1, and PMS-2 was per-
formed on tumor samples. IHC demonstrated loss of
nuclear expression of MSH-2 and MSH-6 with
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brother indicated a germline mutation in MSH-2.
Based on these results a diagnosis of MTS was
suspected, although our patient had not yet had an
internal malignancy. The patient underwent
screening colonoscopy, which revealed negative
findings for colorectal carcinoma.
Less than 1 year later the patient began experi-
encing episodes of expressive aphasia, visual distur-
bance, and memory difficulty. Magnetic resonance
imaging revealed scattered lesions in the left tempo-
ral lobe and left putamen (Fig 2). Biopsy specimen of
the lesions confirmed the diagnosis of glioblastoma
multiformeWorld Health Organization grade IV. IHC
was performed on tumor specimens, which demon-
strated loss of expression of MSH-2 and MSH-6 with
maintained expression ofMLH-1, consistent with his
diagnosis of MTS (Fig 3).DISCUSSION
MTS is a variant of Lynch syndrome with seba-
ceous and internal neoplasms demonstrating micro-
satellite instability and mutations in the mismatch
repair (MMR) genes MSH-2, MLH-1, and MSH-6.4,5
The internal malignancies most commonly associ-
ated with MTS include: colorectal, urogenital, breast,
and upper gastrointestinal.6 Sebaceous neoplasmsJAAD Case Reports 2015;1:381-3.
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Fig 1. Orange-yellow papule with telangectasis located
on left side of neck of 69-year-old Caucasian man.
Fig 2. T2 fluid-attenuated inversion recovery magnetic
resonance imaging of glioblastoma multiforme in left
temporal lobe.
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of internal malignancy in 28% to 41% of patients with
MTS.2,6 Glioblastoma multiforme occurs in 1.2% to
6.3% of patients with MSH-2 mutation dependent
Lynch syndrome, but is not commonly reported in
patients given a diagnosis of MTS.7,8
Our patient had an extensive history of sebaceous
neoplasms including 4 cases of sebaceous carcinoma
and 2 cases of sebaceous adenoma. The sebaceous
neoplasms in our patient predated the development
of CNS malignancy by 11 years. Interestingly, routine
screening colonoscopies revealed negative results
for both our patient and his brother. Although the
patient’s mother and maternal grandfather had an
extensive cancer history including diagnosis in their
early 40s, neither of them were aware of the Lynch
syndrome diagnosis. Our patient was the only mem-
ber of his family to develop sebaceous neoplasms
characteristic of MTS.
A recent report by Kurtzman et al3 described 7
cases of CNS malignancy occurring in patients given
a diagnosis of MTS. In each of the previous cases a
diagnosis of colorectal carcinoma (age 41-50 years)preceded the diagnosis of CNS malignancy. This was
notably absent in our patient. Sebaceous adenoma
was the most commonly diagnosed sebaceous
neoplasm in these cases (5 of 7 patients), whereas
sebaceous carcinoma was diagnosed in 3 of 7
patients. Sebaceous adenomas occurred as multiple
neoplasms in all but 2 patients, whereas sebaceous
carcinomas occurred as isolated lesions in all but our
patient. Sebaceous neoplasms were diagnosed be-
tween the ages of 46 and 58 years. Five of the patients
also reported a previous diagnosis of squamous cell
carcinoma or keratoacanthoma. CNS malignancy
occurred between the ages of 45 and 68 years.
A family history of CNSmalignancywas positive in
a majority of reported cases (6 of 7), which was also
absent from our patient. Among patients given a
diagnosis of Lynch syndrome there is heterogeneity
of tumor development dependent on whether MSH-
2 orMLH-1 is mutated.8 Mutations inMSH-2 aremore
commonly associatedwith CNS and upper urogenital
carcinomawhen comparedwithmutations inMLH-1,
which are more commonly observed in patients with
gastric and small bowel carcinoma. The predilection
for upper urogenital tract carcinoma is consistent
with our patient’s family history. Several studies have
examined MMR mutation frequencies within MTS,
showing mutations in MSH-2 predominating over
MLH-1, althoughmutations inMLH-1 are identified in
a proportion of patients.4,9,10 It is important to note
that all reported cases of CNS malignancy occurring
in patients with MTS who underwent IHC demon-
strated loss of function of MSH-2.3
Loss of nuclear expression of MSH-2 or MLH-1 in
sebaceous neoplasms does not in itself defineMTS. A
significant number of sebaceous neoplasms demon-
strate sporadic mutations in MMR genes resulting in a
low specificity (48%) and positive predictive value
(PPV) (22%) of MMR IHC in diagnosing MTS in
patients without other history suggestive of the
diagnosis.11 However, among patients with multiple
sebaceous neoplasms ($ 2), early diagnosis of
sebaceous neoplasms (age\60 years), or a personal
or family history of Lynch syndrome or related
cancer, the specificity of MMR IHC increases signif-
icantly.12,13 Once the diagnosis of MTS is established
screening recommendations for associated malig-
nancies are variable but generally include increased
frequency and lower threshold for screening related
to colon, breast, endometrial, urogenital, and small
bowel carcinoma.1 Kurtzman et al3 also suggest
neurologic screening as a component of routine
cancer screening for patients with MTS. They suggest
a baseline neurologic examination be performed at
the time of MTS diagnosis and repeated annually.
They also suggest that patients with a family history
Fig 3. Immunohistochemical staining for MSH-2 (A) and MLH-1 (B) in glioblastoma tumor
sections. Staining of sebaceous carcinoma showed similar staining pattern. Note the absence of
MSH-2 nuclear staining and the maintenance of MLH-1 nuclear staining.
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early detection of CNS malignancy.
Although colon cancer is the most common initial
internal malignancy in MTS, we report a case of CNS
malignancy occurring in absence of preceding colo-
rectalmalignancy and in the absence of family history
of CNS malignancy. Furthermore we would like to
note that 100% of patients who underwent MMR IHC
for CNS malignancy, including our patient, demon-
strated loss of expression ofMSH-2 andmaintenance
of MLH-1. Although MSH-2 mutations are by far the
most common MMR mutations among patients with
MTS this association further suggests loss of expres-
sion ofMSH-2 as a risk factor for development of CNS
malignancy. All patients with MTS who develop
neurologic symptoms should have a low threshold
for evaluationof possible CNSmalignancy, especially
those with family history of CNS malignancy or
known MSH-2 germline mutations.REFERENCES
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